Teva’s merger is still in fog

There are spreading rumors that Israel generic giant Teva would acquire majority stocks of a Korean mid-sized pharmaceutical firm worth 100 billion won, but the details are yet unidentified.

Several companies, including Myunmoon Pharm, Korea United, Kukje Pharm and Yuyu Pharm, dismissed the corporate merger in their recent regulatory filings.

Until recently, a couple of Korean firms has y...